Should Southwest Gas (SWX) Return To Profitability And Reaffirmed 2026 Guidance Require Action From Investors?

• Southwest Gas Holdings, Inc. recently reported second-quarter 2026 results showing sales of US$358.15 million and net income of US$42.12 million, alongside reaffirmed full-year earnings guidance of US$4.17–US$4.32 per share from continuing operations.
• The shift from a net loss in the prior-year quarter to positive earnings this year highlights the impact of restructuring and operational improvements on profitability.
• We’ll now examine how Southwest Gas Holdings’ return to quarterly profitability and reaffirmed 2026 earnings guidance affect its existing investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

Southwest Gas Holdings Investment Narrative Recap

To own Southwest Gas Holdings, you need to be comfortable with a regulated gas utility that is trying to convert population growth and infrastructure spending into steady earnings, while facing long term decarbonization and regulatory pressures. The latest quarter’s return to profitability and reaffirmed 2026 EPS guidance suggest no material change to the near term catalyst of execution on its core utility operations, but the risk of tightening environmental and capital recovery rules remains front of mind.

The most relevant recent announcement here is the reaffirmed full year 2026 earnings per share guidance of US$4.17 to US$4.32 from continuing operations, repeated again alongside the Q2 result. That consistency matters for investors watching how leadership navigates post restructuring utility performance and ongoing regulatory proceedings, because it frames expectations around whether infrastructure investment and cost control can offset softer sales and the potential for stricter limits on future capital recovery.

Yet investors should be aware that if regulators further restrict cost recovery for new gas infrastructure, the company’s ability to earn an adequate return on large projects such as...

Read the full narrative on Southwest Gas Holdings (it's free!)

Southwest Gas Holdings’ narrative projects $2.3 billion revenue and $463.3 million earnings by 2029. This requires 9.4% yearly revenue growth and about a $179 million earnings increase from $284.3 million today.

Uncover how Southwest Gas Holdings' forecasts yield a $102.43 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for Southwest Gas range widely, from US$32.31 to about US$102.43, highlighting sharply different views among individual investors. Against that backdrop, the company’s reaffirmed 2026 EPS guidance keeps the focus on whether regulated returns and infrastructure spending can support its current earnings profile over time.

Explore 3 other fair value estimates on Southwest Gas Holdings - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Southwest Gas Holdings research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Southwest Gas Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Southwest Gas Holdings' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com